These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 15674856

  • 1. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
    Brewster AM, Christo DK, Lai H, Helzlsouer K.
    Cancer; 2005 Mar 15; 103(6):1147-53. PubMed ID: 15674856
    [Abstract] [Full Text] [Related]

  • 2. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
    Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, Antman KH, Neugut AI.
    Cancer J; 2000 Mar 15; 6(3):169-78. PubMed ID: 10882333
    [Abstract] [Full Text] [Related]

  • 3. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S.
    Cancer; 2005 May 15; 103(10):1996-2005. PubMed ID: 15825209
    [Abstract] [Full Text] [Related]

  • 4. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M.
    Cancer; 2004 May 01; 100(9):1800-6. PubMed ID: 15112259
    [Abstract] [Full Text] [Related]

  • 5. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL, Becker RV, Gradishar WJ, Gore M, Trotter JP.
    Am J Manag Care; 1999 Jun 01; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [Abstract] [Full Text] [Related]

  • 6. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.
    J Natl Cancer Inst; 2005 Nov 16; 97(22):1652-62. PubMed ID: 16288118
    [Abstract] [Full Text] [Related]

  • 7. Breast cancer risk in primary care: implications for chemoprevention.
    Lewis CL, Kinsinger LS, Harris RP, Schwartz RJ.
    Arch Intern Med; 2004 Sep 27; 164(17):1897-903. PubMed ID: 15451765
    [Abstract] [Full Text] [Related]

  • 8. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.
    J Natl Cancer Inst; 2006 Jan 18; 98(2):110-5. PubMed ID: 16418513
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Italian study on the chemoprevention of breast cancer with tamoxifen].
    Veronesi U, Costa A, Sacchini V, Luini A, Bonanni B, Veronesi P, Rotmensz N, Boyle P.
    Contracept Fertil Sex; 1995 Apr 18; 23(4):258-60. PubMed ID: 7757133
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reducing the risk of breast cancer with tamoxifen in women at increased risk.
    Vogel VG.
    J Clin Oncol; 2001 Sep 15; 19(18 Suppl):87S-92S. PubMed ID: 11560980
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina.
    Bradbury BD, Lash TL, Kaye JA, Jick SS.
    Cancer; 2005 Mar 15; 103(6):1114-21. PubMed ID: 15712362
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J, Kuenneth C, Helms LJ, Barnato A, Kuppermann M, Birch S, Nuovo J.
    Cancer; 2006 Sep 01; 107(5):950-8. PubMed ID: 16865680
    [Abstract] [Full Text] [Related]

  • 17. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA, Land SR.
    Menopause; 2008 Sep 01; 15(4 Suppl):797-803. PubMed ID: 18596601
    [Abstract] [Full Text] [Related]

  • 18. Tamoxifen for breast cancer prevention: a framework for clinical decisions.
    Cykert S, Phifer N, Hansen C.
    Obstet Gynecol; 2004 Sep 01; 104(3):433-42. PubMed ID: 15339751
    [Abstract] [Full Text] [Related]

  • 19. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
    Li CI, Malone KE, Saltzman BS, Daling JR.
    Cancer; 2006 May 15; 106(10):2104-12. PubMed ID: 16604564
    [Abstract] [Full Text] [Related]

  • 20. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N.
    J Natl Cancer Inst; 2006 Jul 05; 98(13):904-10. PubMed ID: 16818854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.